Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tisotumab vedotin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| tisotumab vedotin | DRUG | Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Tisotumab vedotin is an antibody-drug conjugate being developed by Genmab A/S for the treatment of solid tumors. It is an investigational therapy that combines an antibody with a cytotoxic payload to deliver treatment directly to cancer cells. It is currently in Phase 2 clinical development.
Tisotumab vedotin is being studied for use in patients with advanced solid malignancies. It is not yet approved for any indication and remains an investigational agent in clinical development. The research focuses on its potential in oncology as a targeted treatment for solid tumors.
Tisotumab vedotin is being developed by Genmab A/S, a biotechnology company listed on the Nasdaq under the ticker GMAB. Genmab is responsible for the clinical development of the drug, which is currently in Phase 2 trials for solid tumors.
Tisotumab vedotin is in Phase 2 clinical development. It has completed one Phase 1/Phase 2 trial in Japanese subjects with advanced solid malignancies. The drug is investigational and has not been approved by the FDA for any indication.
Tisotumab vedotin has been evaluated in a completed Phase 1/Phase 2 trial, NCT03913741, titled "A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies." The trial enrolled 23 participants and was an uncontrolled study assessing the drug in solid tumors.